Sanofi-Aventis board vacancy
Executive Summary
Aventis business development head and board member Thomas Hoefstatter announces plans to resign. He was expected to serve on the 18-member management committee of the newly merged company's board, and would have been one of 10 representatives of Aventis. Sanofi-Aventis says it is too soon to know how it will proceed with the management and board vacancy, but that it will meet its deadline for putting the new operational structure in place by Jan. 1 (1"The Pink Sheet" Aug. 2, 2004, p. 3)...
You may also be interested in...
Sanofi-Aventis Merger Clears FTC; Estorra Rights To Be Divested
Sanofi and Aventis will begin integrating management and operations following the Federal Trade Commission's July 28 approval of the merger of the two companies
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.